Participant flow

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma · Source last updated 2021-05-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   GROUP A: Standard of care mobiliation: Bortezomib (1.3 mg/m2) in the evening after completion of mobilization with G-CSF

   id

   FG000

   title

   A. Standard of Care Mobilization

2. description

   GROUP B: Bortezomib (1.3 mg/m2) IV on days 4 and 7 (if needed)

   id

   FG001

   title

   GROUP B: Alternative Mobilization

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Protocol Violation

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         2

      type

      Withdrawn prior to Velcade

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         20

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         17

      comment

      1 withdrew consent prior to Velcade infusion 1 removed from protocol prior to Velcade infusioin 1 failed to comply with protocol requirement to come to transplant in 2 months

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice